C-6WKEHeartseed Inc.
iPS cells, cardiac regenerative medicine, remuscularization
replacementreplacingcell therapy
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-6WKE
C-6WKEC-6WKEiPS cells, cardiac regenerative medicine, remuscularization
0-100 chain-logic scale · 15 dimensions · scored on public evidence
The purpose of this clinical study is to evaluate the safety and efficacy of endocardial delivery of HS-001 CS into severe heart failure patients with reduced ejection fraction for 26 weeks after transplantation.
The purpose of this clinical study is to evaluate the safety and efficacy of HS-001 CS transplanted into severe heart failure patients with underlying ischemic heart disease for 26 weeks after transplantation.